(Q43727375)

26 November 2017

0 references

Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis (English)

1 reference

26 November 2017

0 references

6

Nicola De Stefano

1 reference

26 November 2017

Maria Pia Sormani

1

1 reference

26 November 2017

Bettina Stubinski

2

1 reference

26 November 2017

Peter Cornelisse

3

1 reference

26 November 2017

Sanda Rocak

4

1 reference

26 November 2017

David Li

5

1 reference

26 November 2017

9 December 2010

1 reference

Multiple Sclerosis Journal

26 November 2017

1 reference

26 November 2017

17

1 reference

26 November 2017

541-549

1 reference

26 November 2017

5

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

26 November 2017

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Estimating the proportion of treatment effect explained by a surrogate marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Predictors of relapse rate in MS clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Statistical challenges in the evaluation of surrogate endpoints in randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

MRI as an outcome in multiple sclerosis clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458510391837

21 January 2018

Identifiers

DOI

10.1177/1352458510391837

1 reference

26 November 2017

1 reference